Protea Biosciences (PRGB) 0.6000 $PRGB
Protea Biosciences and InSphero AG Enter Into Collaboration and Co-Marketing Agreement to Combine 3D Technologies
GlobeNewswire - Wed Jul 09, 7:30AM CDT
Protea to Apply Direct 3D Molecular Imaging Platform to InSphero's 3D InSight(TM) Microtissues
Protea Announces Presence at 62nd American Society of Mass Spectrometry Annual Conference June 15 - 19, 2014 at the Baltimore Convention Center
GlobeNewswire - Thu Jun 12, 3:00PM CDT
Protea Biosciences Group, Inc. (OTCQB
RGB) ("Protea"
announced today that it will be attending the American Society of Mass Spectrometry Annual Conference in Baltimore, MD. The Conference will take place at the Baltimore Convention Center, located at 1 West Pratt Street, Baltimore, MD 21201 from Sunday June 15 through Thursday June 19.
Protea Announces Alzheimer's Research Collaboration With the University of Southampton, U.K.
GlobeNewswire - Thu May 29, 7:31AM CDT
Protea Biosciences Group, Inc. (OTCQB RGB) announced it has entered into a research collaboration with the University of Southampton, a leading biomedical and clinical research institution located in the United Kingdom. The collaboration will partner Protea's proprietary direct molecular imaging technology and capabilities with a team of Alzheimer's researchers at the University of Southampton, to study the molecular mechanisms of the aged brain, in order to identify markers that may indicate risk of developing Alzheimer's disease.
Protea Biosciences Group's common stock awarded DWAC/FAST share transfer approval
M2 - Fri May 23, 5:21AM CDT
Molecular information company Protea Biosciences Group (OTCQB RGB) stated on Thursday that the Depository Trust Corporation (DTC) has authorised its common stock for DWAC/FAST transfer through its transfer agent, Island Stock Transfer.
Protea Biosciences Announces That Its Common Stock is Now DTC DWAC/FAST Eligible
GlobeNewswire - Thu May 22, 8:43AM CDT
Protea Biosciences Group, Inc. (OTCQB RGB) announced that the Depository Trust Corporation (DTC) has approved its common stock for DWAC/FAST transfer through Island Stock Transfer, the Company's transfer agent. With DWAC/FAST transfer capabilities, Protea's shareholders can now electronically transfer their shares of common stock purchased or sold in the open market, eliminating the need to transfer physical certificates.
Protea to Present at 2014 Needham Healthcare Conference
GlobeNewswire - Tue Apr 01, 9:00AM CDT
Protea Biosciences Group, Inc. ("Protea" announced today that Steve Turner, Protea's CEO, will present at the Needham & Company 13 Annual Healthcare Conference on Tuesday, April 8, 2014 at 11:20 AM, at the Westin Grand Central Hotel in New York City. Mr. Turner will provide a corporate update and will be available for one-on-one meetings with conference attendees.
Protea Announces 2013 Year-End Results and Key Developments
GlobeNewswire - Mon Mar 31, 7:15AM CDT
Protea Biosciences Group, Inc. ("Protea" released its 2013 results today reporting total revenue for the fiscal year ended December 31, 2013 of $1.22 million. This represents a 47% increase over Protea's fiscal year 2012 total revenue and is the first fiscal year that total revenues exceeded $1.0 million. This increase in revenue is the result of sales of the Company's LAESI instrument platform.
Protea Biosciences and InSphero AG Enter Into Collaboration and Co-Marketing Agreement to Combine 3D Technologies
GlobeNewswire - Wed Jul 09, 7:30AM CDT
Protea to Apply Direct 3D Molecular Imaging Platform to InSphero's 3D InSight(TM) Microtissues
Protea Announces Presence at 62nd American Society of Mass Spectrometry Annual Conference June 15 - 19, 2014 at the Baltimore Convention Center
GlobeNewswire - Thu Jun 12, 3:00PM CDT
Protea Biosciences Group, Inc. (OTCQB
RGB) ("Protea" announced today that it will be attending the American Society of Mass Spectrometry Annual Conference in Baltimore, MD. The Conference will take place at the Baltimore Convention Center, located at 1 West Pratt Street, Baltimore, MD 21201 from Sunday June 15 through Thursday June 19. Protea Announces Alzheimer's Research Collaboration With the University of Southampton, U.K.
GlobeNewswire - Thu May 29, 7:31AM CDT
Protea Biosciences Group, Inc. (OTCQB
RGB) announced it has entered into a research collaboration with the University of Southampton, a leading biomedical and clinical research institution located in the United Kingdom. The collaboration will partner Protea's proprietary direct molecular imaging technology and capabilities with a team of Alzheimer's researchers at the University of Southampton, to study the molecular mechanisms of the aged brain, in order to identify markers that may indicate risk of developing Alzheimer's disease. Protea Biosciences Group's common stock awarded DWAC/FAST share transfer approval
M2 - Fri May 23, 5:21AM CDT
Molecular information company Protea Biosciences Group (OTCQB
RGB) stated on Thursday that the Depository Trust Corporation (DTC) has authorised its common stock for DWAC/FAST transfer through its transfer agent, Island Stock Transfer. Protea Biosciences Announces That Its Common Stock is Now DTC DWAC/FAST Eligible
GlobeNewswire - Thu May 22, 8:43AM CDT
Protea Biosciences Group, Inc. (OTCQB
RGB) announced that the Depository Trust Corporation (DTC) has approved its common stock for DWAC/FAST transfer through Island Stock Transfer, the Company's transfer agent. With DWAC/FAST transfer capabilities, Protea's shareholders can now electronically transfer their shares of common stock purchased or sold in the open market, eliminating the need to transfer physical certificates. Protea to Present at 2014 Needham Healthcare Conference
GlobeNewswire - Tue Apr 01, 9:00AM CDT
Protea Biosciences Group, Inc. ("Protea"
announced today that Steve Turner, Protea's CEO, will present at the Needham & Company 13 Annual Healthcare Conference on Tuesday, April 8, 2014 at 11:20 AM, at the Westin Grand Central Hotel in New York City. Mr. Turner will provide a corporate update and will be available for one-on-one meetings with conference attendees. Protea Announces 2013 Year-End Results and Key Developments
GlobeNewswire - Mon Mar 31, 7:15AM CDT
Protea Biosciences Group, Inc. ("Protea"
released its 2013 results today reporting total revenue for the fiscal year ended December 31, 2013 of $1.22 million. This represents a 47% increase over Protea's fiscal year 2012 total revenue and is the first fiscal year that total revenues exceeded $1.0 million. This increase in revenue is the result of sales of the Company's LAESI instrument platform. 
